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Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease characterized by progressive weak-
ness from loss of motor neurons. The fundamental pathogenic mechanisms are unknown and recent evidence
is implicating a signiﬁcant role for abnormal exon splicing and RNA processing. Using new comprehensive
genomic technologies, we studied exon splicing directly in 12 sporadic ALS and 10 control lumbar spinal
cords acquired by a rapid autopsy system that processed nervous systems speciﬁcally for genomic studies.
ALS patients had rostral onset and caudally advancing disease and abundant residual motor neurons in this
region. We created two RNA pools, one from motor neurons collected by laser capture microdissection and
one from the surrounding anterior horns. From each, we isolated RNA, ampliﬁed mRNA, proﬁled whole-
genome exon splicing, and applied advanced bioinformatics. We employed rigorous quality control measures
at all steps and validated ﬁndings by qPCR. In the motor neuron enriched mRNA pool, we found two distinct
cohorts of mRNA signals, most of which were up-regulated: 148 differentially expressed genes (P   10
23)
and411aberrantlysplicedgenes(P   10
25).Theaberrantlysplicedgeneswerehighlyenrichedincelladhesion
(P   10
257),especiallycell–matrixasopposedtocell–celladhesion.Mostoftheenrichinggenesencodetrans-
membrane or secreted as opposed to nuclear or cytoplasmic proteins. The differentially expressed genes were
not biologically enriched. In the anterior horn enriched mRNA pool, we could not clearly identify mRNA signals
or biological enrichment. These ﬁndings, perturbed and up-regulated cell–matrix adhesion, suggest possible
mechanisms for the contiguously progressive nature of motor neuron degeneration. Data deposition:
GeneChip raw data (CEL-ﬁles) have been deposited for public access in the Gene Expression Omnibus
(GEO), www.ncbi.nlm.nih.gov/geo, accession number GSE18920.
INTRODUCTION
Amyotrophic lateral sclerosis (ALS) is an adult-onset idio-
pathic fatal neurodegenerative disease caused by highly selec-
tive loss of motor neurons (1). The main clinical features are
insidious onset of upper and lower motor neuron degeneration
and relatively linear progression over time. The main neuro-
pathological features are loss of motor neurons. The age at
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Advance Access published on November 13, 2009onset is usually over 25 years and incidence increases slightly
with age. The overall incidence of ALS is 2–3 per 100 000
and the prevalence is 6–10 per 100 000. Ninety to 95% of
cases are sporadic (SALS) and 5–10% of cases are familial
(FALS), for which 30% of the mutations have been ident-
iﬁed to date. There are no effective treatments and death
occurs in 90% of patients within 3–5 years. The mechanisms
for the highly selective degeneration are unknown (2) and it is
increasingly thought that non-neuronal cells are involved in
the process (3,4). It is now recognized that close associations
between ALS and frontotemporal lobar dementia with ubiqui-
tin and TDP-43 positive immunoreactivity exist at the clinical,
pathological, and molecular levels (5).
Alternative exon splicing is now believed to be one of the
major factors determining the complexity and functionality
of the eukaryotic genome (6–8). It is one of the main mechan-
isms of gene and cell regulation, modulates the properties of
encoded proteins by regulating expression and adding and
deleting functional domains and likely involves most genes.
The control of exon splicing involves regulatory proteins
binding to a variety of sites on transcripts such as exon spli-
cing enhancers that bind SR proteins, polypyrimidine tracts,
and splice motifs. The primary mediator of splicing is the spli-
ceosome, composed of over 100 splicing factors including pro-
teins, RNA and small nuclear ribonucleoproteins, which
associate with pre-mRNA to mediate intron excision and
exon ligation (9). Abnormal splicing can result in disease
and the list of diseases attributed to this continues to grow
(10). Appreciation of the signiﬁcance of exon splicing in the
genome has grown recently due to better analytic techniques
(11) and is now entering an even more rapid growth phase
with technology to perform deep sequencing (12).
There is increasing evidence that implicates abnormalities of
RNA processing and exon splicing in ALS pathogenesis (13).
TDP-43, a protein that has known functions in RNA processing
and regulation of exon splicing, mislocalizes from the nucleus
to the cytoplasm in SALS, suggesting its nuclear pre-mRNA
functions are fundamentally compromised (14–16). Mutations
in the TARDBP gene encoding the TDP-43 protein are found
in both FALS and SALS, indicating its role can be primary
(17–19). There is strong evidence that the toxic property
resides in the C-terminal fragments, an architecture that
would likely compromise nuclear functions, including exon
splicing. Recently, the FUS/TLS gene has been identiﬁed in
FALS by virtue of its function in RNA processing (20,21).
Among the other genes identiﬁed to date in ALS as well
other motor neuron degenerative disorders, there is over-
representation of genes encoding proteins that are involved in
RNA processing; these include: SETX, SMN, GARS,
ATXN7, IGHMBP2 and ANG (22). A newly reported associ-
ation has been identiﬁed between ALS and variants of a com-
ponent of RNA polymerase II, elongator protein 3 (23). And
spinal muscular atrophy (SMA), the most common motor
neuron disease in childhood, is caused by homozygous loss of
the SMN1 gene, which plays key roles in exon splicing (24).
Motor phenotypes of ALS indicate that underlying motor
neuron degeneration is a focal process that progresses contigu-
ously along neuronal anatomy (25). Neuropathological stages
can be deﬁned in relation to the site of onset, advanced in the
region of onset and progressively less radially away (26). This
creates opportunity for functional genomics analysis, as
genomic signals can be isolated from regions in early to inter-
mediate stages of degeneration and proﬁled using newly
available laser and microchip technologies (27,28). To
pursue this, we created a tissue repository speciﬁcally for sim-
ultaneous genomic and structural studies, used histopathology
to identify suitable neuron-rich regions, validated RNA quality
and proﬁled exon and gene expression in motor neurons and
its anterior horn microenvironment. Using powerful bioinfor-
matics approaches, we identiﬁed biological signals in motor
neuron enriched mRNA pools that appear to be perturbed in
SALS, the strongest of which is abnormal exon splicing,
especially in cell-matrix adhesion genes. The pathogenesis
of SALS remains elusive and mainly pursued by way of lab-
oratory models of genetic disease—our ﬁndings identify
important new aspects directly in human sporadic disease.
RESULTS
Special processing of CNS coupled with laser capture
microdissection permits collection and selective
enrichment of relevant cellular compartments
for genomic analysis
Major challenges facing genomic analysis of human degenera-
tive disorders of the CNS are precise localization and isolation
of the degenerating compartment and the proper acquisition of
materials. As SALS disease typically exhibits a focal onset
and subsequent spread (25,26), patients whose disease began
in bulbar and arm regions have caudally advancing disease
and often have lumbar regions in relatively early stages of
degeneration at the time of death. To exploit this, we devel-
oped an on-call autopsy system and rapidly harvested their
nervous systems, usually completed within 6 h of death, and
speciﬁcally processed them for downstream genomic and
structural studies. We used histopathology to conﬁrm that
the lumbar regions distal to the site of onset had early or inter-
mediate stage of disease pathology with abundant residual
motor neurons and that they contained TDP-43 cytoplasmic
deposits characteristic of SALS. Based upon this analysis
and upon analysis of RNA quality as discussed below, we
then chose nervous systems from the frozen inventory and col-
lected from them motor neurons by laser capture microdissec-
tion in SALS (n ¼ 12) and controls (n ¼ 10) (Table 1 and
Fig. 1A). After we had completed collection of motor
neurons by microdissection, we collected the remaining
anterior horn region to create a second sample set, reasoning
that this might be important for understanding disease patho-
genesis given the strong evidence for non-autonomous
degeneration in ALS (3,4). For standardization, we studied
lumbar regions in all cases, disease and control.
RNA and microarray quality are high
The success of genomic proﬁling depends upon both RNA and
microarray quality. To ensure RNA quality, we used digital
micro-electrophoresis and performed extensive validation of
RNA quality (Supplementary Material S1). We found that
our human RNA quality was high, RNA quality was sufﬁ-
ciently preserved through the steps of microdissection, and
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necessary for microarray analysis (Fig. 1B). When RNA was
optimal, we proceeded to label it, hybridize it to exon
arrays, and process the arrays to CEL ﬁles. To ensure micro-
array quality, we examined CEL ﬁles in multiple ways (see
Materials and Methods) and we found they were uniformly
high (Supplementary Material S1). We always processed
equal numbers of SALS and controls together to minimize
batch effects and upon completion of the studies, we measured
batch effects and they were minimal (data not shown), indicat-
ing evenness of acquired data between disease and control. We
compared both RNA and microarray quality with our analo-
gous experiments in ALS1 G93A transgenic mice using 30
gene expression arrays, which were performed under ideal
laboratory-controlled conditions, and found they were compar-
able (RNA quality is shown in Figure 1B and CEL ﬁle data are
not shown). Thus, we were reassured of the high quality and
reliability of the signals we acquired with our approach.
Genomic analysis identiﬁes differentially expressed gene
signals in the motor neuron enriched mRNA pool
We next looked at differential gene expression. One of the
main challenges of doing this is ascertaining signiﬁcance
when there are multiple tests and uncertain levels of noise.
To determine noise levels in our data, we created sham test
groups by permuting CEL ﬁle test categories and computing
differential gene expression 10 times and then compared
differential gene expression in our true data with the sham
data (see Materials and Methods). In the motor neuron
enriched mRNA pool, we found robust differential expression
and readily deﬁnable noise levels: we estimate a data-speciﬁc
5% noise threshold of P   10
23 and at this level of signiﬁ-
cance, there are 148 differentially expressed genes in the
true data set and an average of six genes (range 2–12) in
the permuted data sets (Fig. 2A, Table 2 and Supplementary
Material S2). Most of the differentially expressed genes are
up-regulated rather than down-regulated—for a fold change
 1.5, 71 genes are up-regulated and 14 genes are down-
regulated—suggesting increasing rather than decreasing mol-
ecular activity in the motor neuron enriched mRNA pool.
Exon splicing is signiﬁcantly aberrant in the motor neuron
enriched mRNA pool and is distinct from and more
pronounced than differential gene expression
We next looked at exon splicing. To determine aberrant exon
splicing, we used an ANOVA-based analysis that generates
P-values indicating the probability of aberrant splicing occur-
ring in a particular gene. The ANOVA-based analysis separ-
ates out many variables, most importantly overall gene
expression levels. As with differential gene expression, one
of the main challenges is ascertaining signiﬁcance with mul-
tiple tests and uncertain levels of noise and we employed
the same strategy of permutation analysis that we used in ana-
lyzing differential gene expression. In the motor neuron
enriched mRNA pool, we again found robust signals and
readily deﬁnable noise levels: we estimate a data-speciﬁc
5% noise threshold of P 10
25 and at this level of signiﬁ-
cance, there are 411 aberrantly spliced genes in the true data
set and an average of 21 genes (range 5–51) in the permuted
data sets (Fig. 2B, Table 2 and Supplementary Material S2).
Comparing aberrantly spliced genes to differentially expressed
genes, we see a nearly 3-fold greater number (411 versus 148)
using our data-speciﬁc noise levels to deﬁne the respective
cohorts. Analysis of these cohorts indicates only 29 genes
overlap—7% of the 411 aberrantly spliced genes and 21%
of the 148 differentially expressed genes (Fig. 2E)—thus
showing that the cohorts of genes are distinct from each
other. The greater numbers of aberrantly spliced genes than
differentially expressed genes cannot be attributed to the
greater degree of multiple testing since this and other
methods of analysis we used correct for this. As with the
differential gene expression, most of the aberrantly spliced
genes were up-regulated rather than down-regulated. To
examine the architecture of aberrant splicing in these genes,
we classiﬁed splicing abnormalities in the top 100 genes and
found that 56% had changes in internal exons, 51% in 50
regions, 36% in 30 regions and 42% in multiple locations
(both internal and terminal) (data not shown).
The aberrantly spliced genes but not the differentially
expressed genes in the motor neuron enriched mRNA pool
are biologically enriched
One of the main challenges of microarray analysis is ascertain-
ing biological importance of identiﬁed genes—statistical sig-
niﬁcance does not equate to biological signiﬁcance. Multiple
approaches have been designed to meet these challenges
(29,30) and one approach is by scoring enrichment from the
Gene Ontology (GO) (www.geneontology.org) by way of a x
2
test (see Materials and Methods). Accordingly, we calculated
this for both differentially expressed genes and for aberrantly
spliced genes. Enrichment analyses often can be difﬁcult to
interpret and P-values deceptively low and thus in order to
Table 1. Demographic details
Primary
diagnosis
CNS ID
number
Age Gender Site of
onset
Disease
course
(years)
PMI
(h)
SALS 14 73 Female Bulbar 1.5 6
SALS 16 61 Male Arm 2.5 3.5
SALS 17 55 Male Arm 2 3
SALS 18 80 Female Bulbar 2 4
SALS 27 74 Male Bulbar 3.25 4
SALS 33 54 Male Arm 6.5 5
SALS 34 81 Female Bulbar 1 3.5
SALS 35 74 Female Bulbar 5.75 5
SALS 60 58 Female Bulbar 3 3
SALS 63 68 Male Arm 2.5 5
SALS 64 47 Male Arm 3 6.5
SALS 68 72 Female Leg 1.5 4
Control 10 78 Male NA NA 2.5
Control 19 80 Female NA NA 2.5
Control 26 49 Male NA NA 4
Control 39 77 Male NA NA 2
Control 42 61 Male NA NA 6
Control 44 80 Female NA NA 5
Control 55 71 Male NA NA 13
Control 59 73 Male NA NA 8
Control 65 82 Male NA NA 4
Control 67 77 Male NA NA 4
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the 10 permuted data sets using a comparable number of genes.
Analysis of differentially expressed genes in the motor neuron
enriched mRNA pool didnot reveal clearly deﬁnable biological
enrichment above noise levels (Fig. 2C). But enrichment analy-
sis of the aberrantly spliced gene cohort, in contrast, revealed
robust enrichment above noise levels: we estimate a
data-speciﬁc 5% noise level threshold of P 10
220 and at this
level of signiﬁcance, there are 33 pathways in our true data
and an average of 1.6 pathways (range 0–4) in our permuted
Figure 1. Laser capture microdissection (LCM) permits collection of high quality RNA from SALS motor neurons. (A): (A1) This is a low-power transverse
view of SALS lumbar spinal cord stained with H&E before LCM. The rectangle indicates the anterior horn. Note the relative abundance of residual lumbar motor
neurons (purple spots) in this nervous system where disease onset was in arm and respiratory muscles. (A2) Same, after LCM—the small white blanks are where
motor neurons were microdissected. Note the speciﬁcity that is achieved within the complex cytoarchitecture of the spinal cord. (A3) This is a mid-power view of
motor neurons captured and adhering to a thermoplastic polymer ﬁlm on an LCM cap. The cap ﬁts into a microtube for RNA isolation. [Scale bars are 1 mm in
(A1) and (A2) and 100 mm in (A3)]. (B) These are electropherograms (left side of each panel) and digital gels (right side of each panel) generated by digital
micro-electrophoresis that is used to assess RNA quality. The column on the left (B1, B3 and B5) is from a SALS nervous system and the column on the right
(B2, B4 and B6) is from a SOD1 G93A ALS1 transgenic mouse for comparison. The top row (B1 and B2) shows total RNA before processing by laser capture
microdissection (LCM). The middle row (B3 and B4) shows total RNA of motor neurons after isolation by LCM. The bottom row (B5 and B6) shows messenger
RNA from the laser captured motor neurons after ampliﬁcation. The similarities in these tracings illustrate the high quality of RNAs generated from SALS
patient materials.
316 Human Molecular Genetics, 2010, Vol. 19, No. 2data (Fig. 2D and Supplementary Material S2). Some gene sets
have enrichment P-values ,10
257.
The speciﬁc enrichments that we identiﬁed in the motor
neuron enriched mRNA pool are predominately related to
cell adhesion and extracellular matrix (ECM) biology
(Table 3 and Supplementary Material S2). Transmembrane
receptor protein tyrosine kinase activity, vascular endothelial
growth factor receptor activity and regulation of cell motility
were also identiﬁed (Table 3 and Supplementary Material
S2). While the 33 gene sets with P   10
220 contained a
total number of 355 genes, many genes appeared redundantly
in the gene sets and only 111 of these were unique. Of these,
57 speciﬁcally relate to cell adhesion and related functions
(Fig. 3). In the sub-categories of cell adhesion, genes associ-
ated with cell–matrix adhesion and cell–substrate adhesion
were far more abundant than those associated with cell–cell
Figure 2. Microarray analysis robustly identiﬁes disease-associated signals in the SALS motor neuron enriched mRNA pool. (A) This graph shows the cumu-
lative numbers of differentially expressed genes as a function of P-values. In this and in the other graphs, the solid line (arrow) shows the true comparison
between SALS and control and the dashed lines (arrowhead) show sham comparisons of randomly permuted groups and indicate the noise levels in the
data. Highly distinct differential gene expression is identiﬁed. (B) This graph shows the cumulative numbers of aberrantly spliced genes as a function of
P-values. Note not only that signiﬁcant aberrant gene splicing is identiﬁed, but also that the degree of abnormality is greater than seen with differential gene
expression. (C) This graph shows cumulative numbers of Gene Ontology gene sets that enrich the differentially expressed genes identiﬁed in (A) as a function
of P-value. There is no apparent biological enrichment of the differentially expressed genes. (D) This graph shows cumulative numbers of Gene Ontology gene
sets that enrich the aberrantly spliced genes identiﬁed in (C) as a function of P-value. By comparison to differential gene expression, the aberrantly spliced genes
are robustly enriched biologically. (E) Venn diagram comparing differentially expressed and aberrantly spliced genes in the SALS motor neuron enriched RNA
pools. Note that the two cohorts of genes are distinctive and have only slight overlap.
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231 versus P ¼ 10
212, respect-
ively). When examining the 57 genes identiﬁed by cell
adhesion, genes encoding transmembrane (n ¼ 24) and
secreted (n ¼ 21) proteins were more highly represented
than genes encoding nuclear (n ¼ 2) or cytoplasmic (n ¼ 10)
proteins (Table 4). Most of these 57 genes (n ¼ 52) were
up-regulated and only a few (n ¼ 5) were down-regulated,
although the up- and down-regulation did not always meet
statistical signiﬁcance (Fig. 3 and Table 4). A large number
of genes were associated with integrin signaling, representing
both ligands (collagens, laminins, ﬁbronectin) and receptors.
There are no clearly identiﬁable gene signals
in the anterior horn enriched mRNA pool
As previously stated, involvement of the microenvironment
(‘non-neuronal neighbors’) is an important aspect of ALS
pathobiology in transgenic mice expressing mutant SOD1
(3) and thus to study it in SALS, we collected and proﬁled
the entire anterior horn after removal of motor neurons. We
had comparable quality of data as the motor neuron enriched
mRNA pool (Supplementary Material S1) but when applying
the same bioinformatics analyses that we used for the motor
Table 2. Top 25 aberrantly spliced and top 25 differentially expressed genes
Gene
symbol
Gene name RefSeq Alt. splice
P-value
Differential
expression P-value
Fold-change
(A versus C)
# Markers
(exons)
ABCA8 ATP-binding cassette, sub-family A (ABC1), member 8 NM_007168 2.84E–17 0.0147702 2.07853 37
ACADVL Acyl-Coenzyme A dehydrogenase, very long chain NM_000018 0.07572 9.62E-05 21.36709 20
AGTRL1 Angiotensin II receptor-like 1 NM_005161 0.00280309 0.000100449 2.80667 6
AQP4 Aquaporin 4 NM_001650 1.35E-27 1.21E206 3.17926 13
ASPA Aspartoacylase (Canavan disease) NM_000049 0.199691 0.000120487 2.94572 6
C1orf198 Chromosome 1 open reading frame 198 AK096166 2.66E216 0.00111187 1.7294 17
C21orf33 Chromosome 21 open reading frame 33 NM_004649 0.0218155 0.00010392 21.30992 10
C3 Complement component 3 NM_000064 1.89E223 0.00107972 2.39112 43
C4A Complement component 4A (Rodgers blood group) NM_007293 1.88E231 0.000487554 2.3395 48
CENTD1 Centaurin, delta 1 NM_015230 9.18E208 8.68E205 1.86511 37
COG5 Component of oligomeric golgi complex 5 NM_006348 1.79E205 0.000102532 1.63965 28
COL1A2 Collagen, type I, alpha 2 NM_000089 2.02E224 0.0319974 1.44001 47
COL6A3 ollagen, type VI, Calpha 3 NM_004369 3.34E220 0.0945555 1.36456 45
CPVL Carboxypeptidase, vitellogenic-like NM_019029 3.89E211 6.99E206 2.06165 17
CXCL16 Chemokine (C-X-C motif) ligand 16 NM_022059 0.00011424 2.01E205 1.99739 10
DST Dystonin NM_183380 9.73E224 0.323111 1.0925 125
EDNRB Endothelin receptor type B NM_000115 2.64E219 1.64E205 3.01733 17
ELAVL3 ELAV (embryonic lethal, abnormal vision,
Drosophila)-like
NM_032281 1.12E205 0.000109817 22.14778 18
EXOSC6 Exosome component 6 NM_058219 0.804989 0.000105887 21.21483 7
FAM46C Family with sequence similarity 46, member C NM_017709 6.43E208 0.000117789 2.4746 6
FLJ21963 FLJ21963 protein NM_024560 2.64E212 2.35E205 3.01776 17
FLJ44874 FLJ44874 protein AK126822 0.597731 1.44E207 21.46746 3
FLNC Filamin C, gamma (actin-binding protein 280) NM_001458 2.80E216 0.289023 1.0877 48
FN1 Fibronectin 1 NM_212482 2.24E221 0.0133788 2.50828 63
HIF3A Hypoxia inducible factor 3, alpha subunit NM_022462 6.33E216 0.0968477 1.24509 27
HLA-B Major histocompatibility complex, class I, B NM_005514 0.011742 0.000145132 2.07808 3
HLA-DMB Major histocompatibility complex, class II, DM beta NM_002118 0.00334092 0.000122339 2.64162 3
HLA-DRA Major histocompatibility complex, class II, DR alpha NM_019111 0.0176529 9.96E206 3.75813 9
INPP5D Inositol polyphosphate-5-phosphatase, 145 kDa NM_005541 2.28E215 0.00485491 1.54023 25
KIAA0644 KIAA0644 gene product NM_014817 5.30E218 0.0764209 1.16279 15
KRT73 Keratin 73 NM_175068 0.156092 6.78E205 21.35392 9
LRP1 Low-density lipoprotein-related protein 1
(alpha-2-macroglo
NM_002332 2.68E219 0.0219457 1.28675 105
MACF1 Microtubule-actin cross-linking factor 1 NM_012090 7.85E222 0.00408213 1.24486 115
MYBPC1 Myosin binding protein C, slow type NM_002465 1.90E221 0.00967833 1.31138 31
OR2W3 Olfactory receptor, family 2, subfamily W, member 3 NM_001001957 0.602669 0.000100305 21.45266 13
OR5AS1 Olfactory receptor, family 5, subfamily AS, member 1 NM_001001921 0.548751 0.000141626 21.3982 3
PADI2 Peptidyl arginine deiminase, type II NM_007365 9.72E214 0.000114651 1.6916 18
PARP9 Poly (ADP-ribose) polymerase family, member 9 NM_031458 0.606104 2.15E205 3.48026 3
PCDHGC5 Protocadherin gamma subfamily C, 5 NM_018929 2.24E221 0.00182203 1.23154 100
PYGM Phosphorylase, glycogen; muscle (McArdle syndrome,
glycogen
NM_005609 7.14E219 0.000661684 1.64136 20
SEMA5B Sema domain, seven thrombospondin Repeats (type 1 and NM_001031702 6.12E225 0.746505 1.02067 31
SF1 Splicing factor 1 NM_004630 3.25E218 0.0117229 1.26463 32
SLC1A3 Solute carrier family 1 (glial high afﬁnity glutamate
transporter)
NM_004172 3.81E205 0.000106293 2.50395 15
SLC35A4 Solute carrier family 35, member A4 NM_080670 0.793629 7.95E205 21.49356 8
SLC4A4 Solute carrier family 4, sodium bicarbonate co-transporter NM_001098484 1.64E216 0.000145173 2.17261 31
TJP2 Tight junction protein 2 (zona occludens 2) NM_004817 9.14E216 0.000452437 2.01894 31
TRBV19 T-cell receptor beta variable 19 BC073930 1.48E215 0.695085 1.02684 30
UTRN Utrophin NM_007124 1.56E220 0.00473928 1.78074 74
318 Human Molecular Genetics, 2010, Vol. 19, No. 2neuron enriched pool, we could not identify any mRNA gene
signals above noise levels either by way of differential gene
expression, aberrant splicing, or biological enrichment (Sup-
plementary Material S3), thus demonstrating the
compartment-speciﬁc nature of our ﬁndings. To better under-
stand this lack of signal in the anterior horn, we examined our
analogous G93A mouse data that used 30 gene expression
arrays and determined signal strength in the anterior horn
and in motor neuron enriched mRNA pools isolated by micro-
dissection using a similar bioinformatics analysis. At both 20
and 60 post-natal days, we identiﬁed signiﬁcant and compar-
able numbers of differentially expressed genes above
experiment-speciﬁc noise levels in both pools (data not
shown), thus demonstrating different strengths of genomic
expression in the relevant histological compartments
between mouse SOD1 and human SALS samples.
The biological enrichments of aberrant exon splicing
in SALS and in an SMA mouse model of motor
neuron degeneration are highly concordant
Recently,exonsplicinginamousemodelofSMAmotorneuron
degeneration using whole genome exon arrays demonstrated
widespread tissue-speciﬁc aberrant splicing, supporting the
hypothesis that functional loss of the SMN1 protein in
spliceosomes and aberrant splicing are fundamental in disease
pathogenesis (24). To compare our ﬁndings to those in this
study in uniform manner, we downloaded the CEL ﬁles of the
spinal cord tissues from this study and processed them the
same way we processed our own. With the bioinformatics
approach reported in the study, 259 genes were identiﬁed as
being aberrantly spliced in the spinal cord. Using our bioinfor-
matics approach estimating data-speciﬁc noise thresholds, 74
genes were identiﬁed (data not shown). By either approach,
there was signiﬁcant aberrant splicing in degenerating tissues.
There was a greater degree of aberrant splicing in our human
SALS tissues (n ¼ 411) than in the SMA mouse model tissues
(n ¼ 74), a difference likely due to greater compartment speci-
ﬁcity in our study using microdissection. While this supports
emerging ideas about a role of exon splicing in motor neuron
diseases, in fact the ability to detect global splicing alterations
is relatively recent with the development of exon arrays and
few studies have been reported. To better understand this, we
next compared the SALS and SMA data with others recently
reportedintheliteratureinnon-motorneurondiseaseconditions
(31,32). We downloaded CEL ﬁles from these studies and pro-
cessedthemthesamewayweprocessedourowndata.Wefound
evengreaterdegreesofaberrantgenesplicingoccurringinthese
other conditions (data not shown), thus reinforcing that impor-
tant biologic functions relate to exon splicing.
Table 3. Biological enrichment of aberrantly spliced genes
Enrichment Enrichment
P-value
% genes in group
that are present
Number of genes
present
Number of genes
in group
GO ID GO category
Biological adhesion 10
258 8.6758 57 657 22610 BP
Cell adhesion 10
258 8.6758 57 657 7155 BP
Basement membrane 10
248 28.9474 11 38 5604 CC
Transmembrane receptor protein tyrosine kinase activity 10
243 20.5882 14 68 4714 MF
Collagen 10
243 28.5714 10 35 5581 CC
Extracellular matrix structural constituent 10
242 18.75 15 80 5201 MF
Vascular endothelial growth factor receptor activity 10
242 50 6 12 5021 MF
Laminin-1 complex 10
241 62.5 5 8 5606 CC
Laminin complex 10
241 62.5 5 8 43256 CC
Transmembrane receptor protein kinase activity 10
241 18.2927 15 82 19199 MF
Regulation of cell migration 10
239 29.0323 9 31 30334 BP
Cell–substrate adhesion 10
231 17.3913 12 69 31589 BP
Cell–matrix adhesion 10
228 17.1875 11 64 7160 BP
Extracellular region part 10
227 6.38003 46 721 44421 CC
Protein binding 10
227 3.32847 228 6850 5515 MF
Plasma membrane part 10
225 4.74517 81 1707 44459 CC
Regulation of cell motility 10
225 14.2857 12 84 51270 BP
Cell–substrate junction assembly 10
225 60 3 5 7044 BP
Cell junction assembly 10
225 60 3 5 34329 BP
Extracellular matrix organization and biogenesis 10
224 19.5122 8 41 30198 BP
Collagen binding 10
223 29.4118 5 17 5518 MF
Phosphate transport 10
223 13.1868 12 91 6817 BP
Hemidesmosome 10
223 100 2 2 30056 CC
Integrin-mediated signaling pathway 10
223 16.3636 9 55 7229 BP
Proteinaceous extracellular matrix 10
222 9.00901 20 222 5578 CC
Regulation of embryonic development 10
222 50 3 6 45995 BP
Stereocilium 10
222 50 3 6 32420 CC
Fibroblast growth factor receptor activity 10
222 50 3 6 5007 MF
Extracellular matrix 10
221 8.77193 20 228 31012 CC
Anatomical structure development 10
221 5.15464 55 1067 48856 BP
Structural molecule activity 10
221 5.91716 40 676 5198 MF
Integrin complex 10
220 21.4286 6 28 8305 CC
Developmental process 10
220 4.04485 101 2497 32502 BP
BP, biological process; MF, molecular function; CC, cellular component.
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ported by enrichment analyses. The SMA mouse model
study also identiﬁed enrichment of ECM biology in the
cohort of aberrantly spliced genes, although quantitative
analysis was not presented and the ﬁnding was not empha-
sized. To compare our ﬁndings to the ones reported in this
study in uniform manner, we sought enrichment the same
way we sought it in ours and we noted comparably robust
enrichment: in the SMA study, we identiﬁed 26 gene sets
with enrichment P   10
220, the cutoff we calculated for
their noise. Some gene sets had enrichment P-values
,10
278. The speciﬁc enrichments were dominantly related
to ECM, collagen, cell adhesion, and related functions (Sup-
plementary Material S2). While the 26 gene sets with enrich-
ment P   10
220 contained a total number of 185 genes, many
genes appeared redundantly in the gene sets and only 48 were
unique. Of these, 32 speciﬁcally relate to ECM, cell adhesion,
and related functions. Of the 48 unique genes from the SMA
study and the 111 unique genes from our SALS study ident-
iﬁed by the respective enrichment analyses, only 5 overlapped
(col12a1, col14a1, fn1, hspg2 and itgb4) (Supplementary
Material S2).
TARDBP/TDP-43, TDP-43 targets and other genes of ALS
interest are mostly normal
We interrogated our data for currently known genes of interest
in SALS pathobiology. A 1.5-fold change of TARDBP has
been previously reported in brains of frontotemporal lobar
dementia with ubiquitinated pathology using microarray
analysis, although the replicates were small and tissue was
not cell-speciﬁc (33). In our array data, we also found that
this might be true in the motor neuron enriched mRNA pool
(1.3-fold change with P ¼ 0.008) but not the anterior horn
enriched mRNA pool, but subsequent qPCR of all 12 SALS
and 10 controls samples did not validate this (data not
shown). TARDBP was normally spliced and we therefore con-
clude TARDBP mRNA transcription is normal in SALS. We
also interrogated our data for known targets of TDP-43—
CFTR, APO A-II, and CDK6—and we found they were
neither differentially expressed nor aberrantly spliced. The
representations for SMN1 and SMN2 are sparse on the array
and what little could be assayed did not demonstrate differen-
tial gene expression (aberrant splicing could not be deter-
mined). We also interrogated our data for currently known
genes of interest in FALS and motor neuron disease biology
other than TARDBP—SOD1, FUS/TLS, SETX, ATXN7,
IGHMBP2, ELP3 and ANG—and they were neither differen-
tially expressed nor aberrantly spliced. As the targets of these
genes are largely unknown, we cannot comment further on
their possible aberrant splicing. Glycyl-tRNA synthetase
(GARS), which is of putative interest in ALS (22), appeared
to demonstrate signiﬁcant down-regulation (21.4-fold
change with P ¼ 0.0006) by microarray but this was not vali-
dated by subsequent qPCR (data not shown). In addition, we
looked at genes identiﬁed by the Gene Ontology as involved
in RNA processing and identiﬁed 39 genes as being either
aberrantly spliced or differentially expressed, although this
biological category was not abnormally enriched by enrich-
ment analysis. We also found that the glutamate transporter
Figure 3. Heat map of the gene expression levels of the 57 cell adhesion genes identiﬁed by their aberrant splicing in the motor neuron enriched mRNA pool in
our study. These 57 genes comprise the cell adhesion biological pathway as deﬁned in the Gene Ontology. They were identiﬁed in our study by virtue of their
marked over-representation in the 411 aberrantly spliced genes identiﬁed in the motor neuron enriched mRNA pool in SALS (P , 10
257). The colored bar indi-
cates the range of intensity values for each gene and the heat maps display their overall gene expression levels, not their aberrant splicing. Note the relatively
clean separation of SALS and control groups and the preponderant up-regulation or over-expression of these genes, which is seen in addition to their aberrant
splicing. (C, control and A, SALS).
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Gene
symbol
Gene name RefSeq Alt. splice
P-value
Differential
expression P-value
Fold change (A
versus C)
Number of
markers
Protein
location
AEBP1 AE binding protein 1 NM_001129 2.44E210 0.0186655 1.69315 27 sec
ANXA9 Annexin A9 NM_003568 8.62E207 0.971328 21.00249 14 cyt
CDH11 Cadherin 11, type 2, OB-cadherin
(osteoblast)
NM_001797 2.94E206 0.00458728 1.65623 21 tm
CDH5 Cadherin 5, type 2, VE-cadherin
(vascular epithelium)
NM_001795 2.36E206 0.102509 1.27449 19 tm
CDH23 Cadherin-like 23 NM_022124 1.61E207 0.156179 1.12818 71 tm
CTNNA3 Catenin (cadherin-associated protein),
alpha 3
NM_013266 6.53E206 0.00648134 1.79781 25 cyt
CTNND2 Catenin (cadherin-associated protein),
delta 2
NM_001332 1.59E206 0.0867763 1.1616 32 cyt
CD44 CD44 molecule (Indian blood group) NM_000610 5.13E212 0.000479249 1.89535 21 tm
CLDN10 Claudin 10 NM_182848 6.03E206 0.162268 1.20723 12 tm
CLDN11 Claudin 11 (oligodendrocyte
transmembrane protein)
NM_005602 1.94E206 0.00435624 1.53442 6 tm
COL3A1 Collagen, type III, alpha 1
(Ehlers-Danlos syndrome type)
NM_000090 3.84E209 0.221719 1.17435 49 sec
COL6A3 Collagen, type VI, alpha 3 NM_004369 3.34E220 0.0945555 1.36456 45 sec
COL11A1 Collagen, type XI, alpha 1 NM_001854 2.33E209 0.178053 1.20705 46 sec
COL12A1 Collagen, type XII, alpha 1 NM_004370 1.69E210 0.0105983 1.79078 69 sec
COL13A1 Collagen, type XIII, alpha 1 NM_005203 6.71E209 0.169929 1.15626 25 sec
COL14A1 Collagen, type XIV, alpha 1 (undulin) NM_021110 1.06E208 0.00638787 1.58704 24 sec
COL27A1 Collagen, type XXVII, alpha 1 NM_032888 1.43E206 0.243964 21.10262 46 sec
CSF3R Colony stimulating factor 3 receptor
(granulocyte)
NM_156039 2.04E206 0.126098 1.10957 24 tm
CYR61 Cysteine-rich, angiogenic inducer, 61 NM_001554 1.17E207 0.0315499 1.55961 8 sec
DDR1 Discoidin domain receptor family,
member 1
NM_013993 4.24E208 0.103136 1.15821 31 tm
DST Dystonin NM_183380 9.73E224 0.323111 1.0925 125 cyt
ENG Endoglin (Osler-Rendu-Weber
syndrome 1)
NM_000118 5.65E206 0.342529 1.19248 20 tm
ERBB2IP Erbb2 interacting protein NM_018695 6.83E207 0.000240051 2.08535 30 cyt
ECM2 Extracellular matrix protein 2, female
organ and adipocyte
NM_001393 4.60E206 0.0461937 1.59777 20 sec
FAT FAT // FAT tumor suppressor
homolog 1 (Drosophila)
NM_005245 1.45E208 0.00159728 1.86066 31 tm
FN1 Fibronectin 1 NM_212482 2.24E221 0.0133788 2.50828 63 sec
HMCN1 Hemicentin 1 NM_031935 7.81E207 0.209353 1.1854 116 sec
HSPG2 Heparan sulfate proteoglycan 2 NM_005529 2.11E209 0.938373 21.00658 101 sec
HEPACAM Hepatocyte cell adhesion molecule NM_152722 2.96E206 0.0223096 1.54885 13 tm
IGSF11 Immunoglobulin superfamily,
member 11
NM_001015887 5.57E208 0.0724414 1.24835 13 tm
ITGA6 Integrin, alpha 6 NM_000210 9.56E208 0.0229754 2.06743 29 tm
ITGAX Integrin, alpha X (complement
component 3 receptor 4 subunit)
NM_000887 7.10E208 0.305373 1.09177 29 tm
ITGB3 Integrin, beta 3 (platelet glycoprotein
IIIa, antigen CD61)
NM_000212 1.12E206 0.394661 1.16482 20 tm
ITGB4 Integrin, beta 4 NM_000213 4.07E215 0.183707 1.14822 44 tm
ITGB7 integrin, beta 7 NM_000889 1.28E212 0.345837 21.07065 17 tm
ITGBL1 ITGBL1 // integrin, beta-like 1 (with
EGF-like repeat domains)
NM_004791 2.24E214 0.00392462 1.97861 16 tm
JAM2 Junctional adhesion molecule 2 NM_021219 3.87E208 0.00548407 2.02731 13 tm
LAMB1 Laminin, beta 1 NM_002291 2.61E213 0.0290629 1.61794 36 sec
LAMB2 Laminin, beta 2 (laminin S) NM_002292 3.16E206 0.155571 1.21405 40 sec
LAMC3 Laminin, gamma 3 NM_006059 8.59E206 0.370666 21.06083 35 sec
LPP LIM domain containing preferred
translocation partner in lip
NM_005578 1.40E206 0.147014 1.51955 13 cyt
MYBPC1 Myosin binding protein C, slow type NM_002465 1.90E221 0.00967833 1.31138 31 cyt
NCAN Neurocan NM_004386 4.77E210 0.206516 1.13639 25 sec
NRP2 Neuropilin 2 NM_003872 5.65E207 0.0447044 1.29315 36 tm
PARVG Parvin, gamma NM_022141 2.03E207 0.015984 1.25824 14 cyt
PDZD2 PDZ domain containing 2 NM_178140 2.86E207 0.0529539 1.34362 44 cyt
PECAM1 Platelet/endothelial cell adhesion
molecule (CD31 antigen)
NM_000442 3.50E206 0.023662 2.42764 17 tm
PCDHGC5 Protocadherin gamma subfamily C, 5 NM_018929 2.24E221 0.00182203 1.23154 100 tm
RELN Reelin NM_173054 3.03E206 0.0459772 1.59369 73 sec
Continued
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ALS (34) was not abnormal, consistent with another report
(35); however, we did observe that two other glutamate trans-
porters, EAAT1 (SLC1A3) and EAAT4 (SLC1A6) might be
differentially expressed (2.5-fold change with P ¼ 0.0001
and 21.2-fold change with P ¼ 0.007, respectively) and
both validated by qPCR (P ¼ 0.025) (Supplementary
Material, S2).
qPCR validates microarray predictions of aberrantly
spliced gene candidates
In order to validate aberrant exon splicing between the SALS
and control as predicted by the exon arrays, 12 candidate
genes were selected and exons within these genes predicted
to exhibit differences and lack of difference were both
assayed by TaqMan qPCR (see Materials and Methods).
These genes were chosen from a variety of biological path-
ways to assay for splicing differences in various biological
processes (Supplementary Material S4). Eight out of the 12
genes or 67% (EDNRB, PAX6, SF1, TMBIM1, TRBV19,
VCAN, ARHGAP15 and AQP4) as illustrated in Figure 4
showed both of the changes predicted by the exon array in
the same gene (Supplementary Material S4). This level of
PCR validation is consistent with or above those in similar
exon array studies (36–38) and we are thus reassured of the
validity of the exon array predictions.
DISCUSSION
We made three key observations, the foundation of which is
summarized in Table 5. The ﬁrst key observation is that
genomic abnormalities in SALS are highly localized to the
motor neuron enriched mRNA pool (the degenerating ana-
tomic compartment) and not apparent in the anterior horn
enriched mRNA pool (the surrounding microenvironment).
The strength of signal in the former and the lack of signal in
the latter (which is itself enriched by removal of nearly 75%
of the surrounding spinal cord) show this and the critical
importance of anatomic and technical precision in identifying
pathologic changes in vivo. The exact identity of the motor
neuron enriched mRNA pool is not entirely clear. In favor
of its mRNA deriving mostly from motor neurons is the ana-
tomic speciﬁcity of microdissection and our preliminary histo-
logical studies of these same tissues in FFPE that do not show
obvious surrounding hypercellularity. In favor of its contain-
ing mRNA also from non-motor cells is the difﬁculty of resol-
ving cell morphology in the frozen cryosections on which
microdissection is performed, the identiﬁcation of biological
enrichment that may be external to the cell itself (cell–
adhesion, cell–matrix and ECM), and the identiﬁcation of a
number of genes that appear to be primarily glial. Thus,
while enriched in microdissected motor neurons, it is possible
that the mRNA signals are also enriched in other proximate
cells or their mRNA-rich processes.
A striking ﬁnding is lack of signal and biologic enrichment
in the anterior horn enriched mRNA pool. While this lack of
signal validates our strategic approach of separating the two
compartments, it is surprising given the strong evidence indi-
cating that motor neuron degeneration is non-autonomous in
mice expressing mutant SOD1 (3,4) and the strong evidence
supporting the role of glia in magnifying the motor neuron
pathology associated with ALS (39–41). In our comparable
data from mutant SOD1 transgenic mice, we did in fact
show equal signal strengths between the motor neuron and
the anterior horn enriched mRNA pools. There are a
number of potential explanations for this difference in
human disease and the mutant SOD1 transgenic mouse
model. In humans, the anterior horn is much larger anatomi-
cally than in mice and the critical interactions may reside in
very close apposition to the neurons and thus detectable in
the motor neuron enriched mRNA pool but diluted in the
anterior horn enriched mRNA pool. In humans, the larger-
sized anterior horn compared with mice may allow greater
cellular heterogeneity and greater noise. In humans, the
changes are sequential and summating, whereas in mice
they are temporally synchronized. In humans, the effects in
the anterior horn may be subtler than in mice and not detect-
able with our bioinformatics-based approach. Or, of course,
non-autonomous cell effects may not be as signiﬁcant in
SALS pathognesis as in the SOD1 mouse model, upon
which most of the non-autonomous cell degeneration litera-
ture is based.
Table 4. Continued
Gene
symbol
Gene name RefSeq Alt. splice
P-value
Differential
expression P-value
Fold change (A
versus C)
Number of
markers
Protein
location
SSPN Sarcospan (Kras oncogene-associated
gene)
NM_005086 1.23E207 0.00153469 1.87677 8 tm
SEMA5A Sema domain, seven thrombospondin
Repeats
NM_003966 6.24E206 0.132723 1.27857 29 tm
SOX9 SRY (sex determining region Y)-box
9 (campomelic dysplasia)
NM_000346 3.07E207 0.584737 1.05446 9 nuc
TNC Tenascin C (hexabrachion) NM_002160 2.55E208 0.125224 1.66206 36 sec
TESK2 Testis-speciﬁc kinase 2 NM_007170 6.75E207 0.0632463 1.36536 14 nuc
TRIP6 Thyroid hormone receptor interactor 6 NM_003302 2.74E207 0.194651 1.16145 13 cyt
VCAN Versican NM_004385 8.36E211 0.000148832 2.61415 26 sec
VWF von Willebrand factor NM_000552 5.40E212 0.085195 1.51082 46 sec
cyt, cytoplasmic; nuc, nuclear; sec, secreted; tm, transmembrane.
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cing is more signiﬁcant and relevant than differential gene
expression in SALS—signals are more clearly identiﬁed and
their biological enrichment more robustly deﬁned by proﬁling
aberrant exon splicing than differential gene expression. This
supports the critical biological (6–8) and pathologic (10)
importance of exon splicing in general and its interest to
ALS (14–24) in particular. TDP-43 is the leading candidate
in SALS pathogenesis and its exact role in pathogenesis is fun-
damental but remains unclear (14). Since one of its main
known functions is exon splicing and in SALS it mislocalizes
from the nucleus to the cytoplasm, it is important to note that
we could not detect expression or splicing changes in its
encoding gene TARDBP or any of its known targets including
CFTR, APO A-II, CDK6 and SMN1. Together, these suggest
that its role in SALS pathobiology is not likely at its own
mRNA level and that it likely involves some other
yet-to-be-identiﬁed targets or mechanisms—to date, a compre-
hensive list of TDP-43 targets and actions has not been
deﬁned. Alternatively, TDP-43 may involve functions other
than exon splicing and the importance of the aberrant splicing
that was detected by us is separate. The important role exon
splicing may play in motor neuron degeneration is highlighted
by SMA (42). SMA is caused by homozygous loss of the SMN
gene, which is essential for biogenesis of small nuclear ribonu-
cleoprotein particles that are critical components of the RNA
Figure 4. Aberrant splicing predictions of the exon arrays validate by qPCR. Four examples of validation of aberrant splicing are demonstrated in this ﬁgure. The
gene views on the left show the expression of exons as determined by exon array; the expression levels are shown on a log2 scale; the error bars show standard
errors of means; SALS, red triangles; control, blue squares. Exons showing similar (A) and different (B) expression between SALS and control (arrows) were
selected for validation by qPCR. The bar plots on the right show the results of qPCR: expression of the selected exons are normalized to GAPDH and shown ona
log2 scale; the error bars show the 95% conﬁdence intervals; SALS, red; control, blue. Asterisks indicate signiﬁcant difference by t-test (a ¼ 0.05) in expression
as predicted by the microarray. In these examples, exons predicted to have differential expression and exons predicted not to have differential expression were
conﬁrmed by qPCR.
Human Molecular Genetics, 2010, Vol. 19, No. 2 323splicing apparatus (43). Thus, splicing abnormalities are
expected to play major roles in motor neuron degeneration
and have been demonstrated in a mouse model to be both
widespread and tissue-speciﬁc, differing within different neur-
onal tissues and between neuronal and non-neuronal tissues
(24). Together with our study, splicing abnormalities are
shown to be cell-speciﬁc as well as tissue-speciﬁc.
The mechanistic bases of the aberrant splicing in ALS are
unclear. A number of RNA processing factors are themselves
aberrantly spliced or differentially expressed in our SALS
samples (Supplementary Material S2), which may provide
an explanation for at least part of the splicing changes in
SALS. We do not know if the genes encoding these RNA pro-
cessing factors are mutated in SALS, similar to FUS/TLS or
TDP-43, or if they are abnormally regulated downstream of
primary disease-causing genes, but they represent interesting
candidates for further analysis. For example, SF1 and
SFRS2 have been shown to associate with FUS/TLS (44,45)
and SFRS2 also alters the splicing of the TDP-43 target
APO A-II (46), while SFRS5 alters the splicing of two
TDP-43 targets (APO A-II and CFTR) (46,47). In addition,
ELAVL3 (HuC) has a role in paraneoplastic neurologic dis-
orders (48) and neuronal development (49). Interestingly,
mutant SOD1 competes with HuC (and HuR) for binding to
the 30-UTR of vascular endothelial growth factor (VEGF)
(50). RNASET2 is of interest due to the potential role of
angiogenin (also an RNase) in ALS (22), as well as the
recently demonstrated effects of RNASET2 loss on neuronal
development (51). PTPBP1 represents a key regulator of neur-
onal development through its effects on repressing neural PTP
(also called PTBP2) (52), as loss of PTPBP1 results in neural
differentiation associated with PTPBP2 activation (53). There
is also recent evidence of PTPBP1 involvement in the prolifer-
ation and migration of gliomas (54).
The third key observation of our study is the speciﬁc identi-
ﬁcation in SALS of perturbation of cell adhesion and ECM
biology, especially cell–matrix as opposed to cell–cell
adhesion genes. Other identiﬁed pathways included transmem-
brane receptor protein tyrosine kinase activity, vascular endo-
thelial growth factor receptor activity [already of great interest
in ALS pathobiology (55)] and regulation of cell motility
(Tables 3 and 5). Since these were only identiﬁed in the
motor neuron enriched mRNA pool and not in the larger sur-
roundings of the anterior horn, their gene action is at or very
proximate to neurons. Most of the cell adhesion genes we
identiﬁed encode proteins that are either secreted or trans-
membrane as opposed to cytosolic or nuclear. The mechan-
isms by which these genes are likely to exert their effects
are on the structure of the encoded proteins because the key
to their identiﬁcation was the aberrant splicing of the exons
in the genes encoding them. Their abnormal action is likely
to be part of an active rather than passive process since they
are also mostly over-expressed or up-regulated. Where in the
cascade of motor neuron degeneration their perturbations
occurs or whether their perturbations are primary or secondary
are unknown—their identiﬁcation depended on pooling motor
neurons within each nervous system and analysis of signals
among multiple nervous systems. But the perturbations argu-
ably are relatively upstream: (i) studies were performed in
regions to which the degenerative process was newly advan-
cing and therefore neuron-rich (in fact, these studies are
only feasible in such regions) (26); (ii) the neurons in these
regions showed relatively inconspicuous changes histologi-
cally when examined in companion FFPE tissues; and (iii)
microdissection has an intrinsic bias for selectively collecting
larger and healthier motor neurons. The studies on the mouse
model of SMA highlight the functional and biological impor-
tance of the speciﬁc perturbations of cell–matrix and ECM
biology: what is most concordant between SALS and SMA
motor neuron degeneration is not aberrant exon splicing per
se—there are only ﬁve genes that overlap—but the nearly
identical and highly robust biological enrichments of the two
distinct aberrant spliced gene cohorts. The source and coordi-
nation of the aberrant splicing is unknown and would only be
identiﬁed by our method if altered in either expression or spli-
cing. While we did observe alterations of RNA processing
factors (mentioned above and Supplementary Material S2),
there are many other possible alterations such as point
mutations or post-translational changes that we are not able
to observe. It is even possible, as demonstrated by SMA,
that alterations in only one factor could cause multiple splicing
abnormalities, but for the same reasons we might not be able
to detect such.
Motor neurons are surrounded by a rich structural as well as
cellular matrix and there are a number of potential scenarios
where altered cell–matrix interactions could signiﬁcantly
affect neuron function. Disruption of cell–matrix molecules
could adversely affect glia as well as neurons, thus resulting
in or resulting from dysfunction of both cell categories (56).
A few possibilities are outlined. (i) Alterations in the ECM
could aberrantly modify the diffusion kinetics of paracrine
factors such as growth factors, purines, etc., resulting in too
Table 5. Summary of key ﬁndings
Motor neuron enriched
mRNA pool
Anterior horn enriched
mRNA pool
Cellularity Homogeneous (single-cell
enriched)
Heterogeneous (glia,
endothelium, small
neurons, degenerating
neurons)
Anatomic size Highly discrete Comparatively vast
Differential gene
expression
148 genes Not detectable above
noise
Biological
enrichment of
differentially
expressed genes
Not detectable abovenoise Not detectable above
noise
Aberrant exon
splicing
411 genes Not detectable above
noise
Biological
enrichment of
aberrantly spliced
genes
Cell–matrix adhesion and
extracellular matrix
biology; also
transmembrane
receptor protein
tyrosine kinase activity,
vascular endothelial
growth factor receptor
activity, and regulation
of cell motility
Not detectable above
noise
324 Human Molecular Genetics, 2010, Vol. 19, No. 2much or too few of these factors reaching adjacent cells (57).
(ii) Alterations in ECM could adversely affect neurons via
integrin adhesion and signaling (58). (iii) Cell–matrix inter-
actions are critical for neuronal migration, which occurs pri-
marily during development as neural progenitor cells
migrate to their proper positions before differentiating (59).
Abnormal cell–matrix interactions could alter the normal for-
mation and wiring of the nervous system, thus priming a
delayed failure (60). (iv) Alterations in the ECM might
cause or reﬂect derangements to the release of or diffusion
of chemoattractants that activate neural progenitor cells and
promote their migration toward diseased structures to try to
‘rescue’ degenerating motor neurons (61); alterations in the
ECM might allow propagation of a maladapted process. (v)
The basal lamina in the CNS, which is comprised predomi-
nately of ECM proteins, serves an important role in modulat-
ing the permeability of the blood brain barrier (62). Cleavage
of proteins in the basal lamina by matrix metalloproteinases
produced by invading inﬂammatory cells is required to facili-
tate their access to the CNS (63), thus alterations in ECM
protein isoforms could alter blood brain barrier permeability.
In addition, we have found that a protein crucial for determin-
ing the water permeability of the blood brain barrier,
aquaporin-4 (62), demonstrates increased expression of a
speciﬁc isoform in SALS (see Results). Overexpression of
aquaporin-4 has been reported in ALS mouse (64) and rat
models (65). It is interesting to note evidence from mouse
ALS models indicating blood brain barrier changes early in
the disease process (66). And (vi), ECM proteins can directly
affect cells or alter the interactions of other ECM proteins with
adjacent cells. For example, the ECM protein versican, which
demonstrates altered splicing in SALS (see Results), is thought
to restrict neuronal plasticity in adults as a component of peri-
neuronal nets (67,68) and is upregulated in a rat model of ALS
(66). Additionally, versican promotes the assembly of hyalur-
onan (69), which can activate microglia though binding to the
CD44 receptor (70) (which also undergoes altered splicing in
SALS).
These three key observations of our study are especially
interesting in light of our recent postulations that motor
neuron degeneration in SALS is an actively spreading and pro-
pagating process (71). That the aberrantly spliced genes are
up-regulated is consistent with the process being active
rather than passive. That the aberrantly spliced genes have per-
turbed cell–matrix and ECM adhesion biology is consistent
with the importance of interactions in the microenvironment
that could advance in space and over time. In this regard, it
is important to note that there are two general types of inter-
neuronal communication: one is synaptic communication
between neurons that are in series (such as between upper
and lower motor neurons or between neurons and inter-
neurons) and the other is local side-to-side communication
between neurons that are in parallel and involves local para-
crine signaling and the neuron microenvironment. The recent
identiﬁcation that one or more soluble factors are selectively
toxic to motor neurons is especially intriguing (72). One of
many scenarios that can be imagined is that perturbed cell
adhesion induces local changes and release of toxic soluble
factors recruiting nearby cells, thus propagating a non-
accelerating pathologic process. In the ﬁnal analysis, our ﬁnd-
ings do not distinguish primary from secondary changes in
pathobiology and add more pieces to the complex puzzle.
Many challenges and questions remain, an immediate one
being biological validation of our largely bioinformatics-based
ﬁndings.
MATERIALS AND METHODS
Tissue acquisition and repository
All nervous systems were acquired by way of an Investiga-
tional Review Board and Health Insurance Portability and
Accountability Act compliant process. The SALS nervous
systems were from patients who had been followed during
the clinical course of their illness and met El Escorial criteria
for deﬁnite ALS (73). Upon death, autopsies were performed
immediately by an on-call tissue acquisition team. Control
nervous systems were from patients from the hospital’s critical
care unit when life support was withdrawn (7), patient on
hospice (1) and from the Pennsylvania Tissue Repository
(2). Tissue collections were completed within 6 h, usually
within 4 h, of death and the entire motor system was dissected
and elaborately archived for downstream applications by
creating two parallel tissue sets from alternating adjacent
regions. For molecular studies, segments were embedded in
cutting media, frozen on blocks of dry ice and stored at
2808C. For structural studies, the adjacent segments were
ﬁxed in 70% neutral buffered formalin, embedded in parafﬁn
(formalin-ﬁxed parafﬁn-embedded or FFPE) and stored at
room temperature.
Microdissection and total RNA isolation
Thirty to forty 8–10 mm cryocut frozen tissue sections stained
with cresyl violet acetate were microdissected from each
nervous system on a Pixcell IIe Laser Capture Microdissection
(LCM) System (Arcturus Bioscience) in a 2-h long epoch for
the motor neuron enriched RNA pool. Microdissected cells
were captured on CapSureTM Macro LCM Caps (Arcturus
Bioscience). After completion of LCM, the surrounding
remaining anterior horn region was collected to create a
second parallel RNA pool. RNA isolations were based on a
guanadinium isothiocyanate and 2-mercaptoethanol
extraction and column puriﬁcation with RNeasy
w Micro Kit
(Qiagen).
mRNA ampliﬁcation and exon array hybridization
For exon proﬁling, total RNA was ampliﬁed to cDNA probe
using random priming with WT-OvationTM Pico RNA Ampli-
ﬁcation System (NuGEN). The antisense–sense orientation
was converted to sense transcript-cDNA (ST-cDNA) using
WT-OvationTM Exon Module (NuGEN). ST-cDNA was frag-
mented and biotin labeled using FL-OvationTM cDNA Biotin
Module v2 (NuGEN). Probe was hybridized to GeneChip
w
Human Exon 1.0 ST Arrays (Affymetrix). This array
determines both exon and gene expression and are more resi-
lient to RNA degradation changes than traditional 30 gene
arrays, which depend solely on integrity of the 30 exon (74).
Hybridized chips were stained and washed on a GeneChip
Human Molecular Genetics, 2010, Vol. 19, No. 2 325450 ﬂuidics Station (Affymetrix) and scanned with a Gene-
Chip 3000 scanner (Affymetrix). Initial data was processed
to CEL ﬁles using GCOS Version 1.4 (Affymetrix). The
microarray data presented herein and deposited in the GEO
is MIAME compliant.
Quality control
RNA quality were assessed using digital microelectrophoresis
with either a PicoChipTM or NanoChipTM (Agilent), which
generated electropherograms, digital gels, and RNA Integrity
numbers (RINs) (75). RNA quality was ascertained at each
stage of processing—acquisition, microdissection, ampliﬁca-
tion, fragmentation—and studies were advanced only if
optimal. Microarray quality was assessed by visualization of
the microarray CEL ﬁles, percent positive calls on the micro-
array, area under the curve (AUC) values, distribution histo-
grams of non-normalized expression scores, box plots of
mean and 25th and 75th percentiles probe scores before and
after quantile normalization, median normalized non-
background corrected scores of probes designated as back-
ground, graphs of mean absolute difference between trans-
formed background-corrected and normalized probe scores
and frequency histograms of GC counts (76).
Bioinformatics
Primary bioinformatics analysis used Genomics Suite Version
6.4 (Partek). CEL ﬁles were imported into the software and
their backgrounds underwent RMA and quantile normaliza-
tions. Statistical analysis was performed by creating from
the individual CEL ﬁles two groups, control or SALS, and
then comparing them to each other. The exon arrays have
three types of probe sets: core, extended and full. The core
probe set contains 17 800 transcript clusters and 284 000
probe sets to RefSeq and GenBank full-length mRNA’s; the
extended probe set contains 129 000 transcript clusters and
523 000 probe sets (plus core probes), with additional
probes to expressed sequence tags (EST’s) and partially anno-
tated mRNA’s; and the full probe set contains 262 000 tran-
script clusters and 580 000 probe sets (plus core and
extended probes) with additional probes to all predicted
exons in the genome. For our analysis, we have used the
core probe set because of the depth of annotation available.
The software uses a proprietary Exon Splice ANOVA algor-
ithm to calculate both each gene’s differential expression,
which is determined by a composite expression of all its
exons comparing between disease and control, and each
gene’s exon splice index, which is determined by
exon-to-exon comparison between disease and control after
correcting for other variables, including overall differential
gene expression. Among the factors measured by the
ANOVA are batch effects. Signal strengths and noise levels
were measured in two ways. First, noise levels speciﬁc to
our data were estimated by randomly permuting CEL ﬁle
classiﬁcations to create comparisons between sham groups;
10 permutations were performed. Second, multiple test correc-
tion was performed by Bonferroni method; these data are
reported in the Supplementary Material. Enrichment analysis
was determined by generating an enrichment score equal to
the P-value of a x
2 test comparing identiﬁed genes and their
biological functionality as deﬁned by Gene Ontology (www.
geneontology.org). Heat maps were generated by ﬁrst sum-
marizing the exons of each gene using the ‘gene summary’
command, followed by the ‘cluster based on signiﬁcant
genes’ command. Additional bioinformatics analysis was per-
formed using Expression ConsoleTM Version 1.1 (Affymetrix)
and XRAY Version 3.92 (Biotique Systems).
Validation of array results by qPCR
Genes identiﬁed as being aberrantly spliced were selected for
validation by qPCR. Exons exhibiting signiﬁcant differences
as well as lack of differences of expression between SALS
and control were analyzed. Target sequences to these exons
were obtained from Affymetrix. To these, primers and
probes were designed using Applied Biosystem’s Primer
Express software program (Applied Biosystems Inc.). In the
case of TDP-43, GARS, EAAT1 (SLC1A3), EAAT4
(SLC1A6) and GAPDH, standard TaqMan
w probes were
used (Applied Biosystems, Inc). qPCR was performed using
either a 7900HT Fast Real Time PCR System or a 7500
Real Time PCR system using either a 384 or 96-well format
(Applied Biosystems, Inc). Four-fold standard dilution
curves were generated on each plate for each probe in an
RT step using RNeasy-puriﬁed HEK 293 RNA (Qiagen).
Test samples consisted of ampliﬁed cDNA from the motor
neuron enriched RNA pools and were run in triplicate. The
resulting data were normalized to endogenous GAPDH
run in parallel on each plate. Values from 3–12 SALS and
3–10 control were separately determined, averaged between
groups, and compared by two-tailed Welch’s t-test using log-
arithmic scaling. We called a gene valid only if two conditions
were both met: an exon predicted to have differential
expression and an exon predicted not to have differential
expression were conﬁrmed by qPCR.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
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